Indeed, multiple clinical trials have demonstrated that CDK4/6 inhibitors combined with ET markedly improve the survival rate of patients with advanced or metastatic HR+/HER2– BC (3, 8–10). The gene discussed is ERBB2; the disease is breast cancer.